Hui-Chen Cheng

Learn More
PURPOSE To investigate the efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for Stage 4 retinopathy of prematurity. METHODS Retrospective case series study. The medical records of patients receiving intravitreal injection of anti-vascular endothelial growth factor agents for Stage 4 retinopathy of prematurity from(More)
IMPORTANCE Previous studies have found that glaucoma is associated with impaired patient-reported vision-related quality of life (pVRQOL) but few, to our knowledge, have assessed how the visual field (VF) defect location impacts the pVRQOL. OBJECTIVE To investigate the associations of VF defects in the superior vs inferior hemifields with pVRQOL outcomes(More)
PURPOSE To introduce a new approach for short-term external scleral buckling with pneumatic retinopexy for the management of rhegmatogenous retinal detachment with inferior retinal breaks. DESIGN Retrospective, noncomparative, interventional case series. METHODS A review of 33 consecutive eyes of 31 patients who underwent external buckling with(More)
BACKGROUND Ectopia lentis et pupillae (ELeP) is a rare congenital inherited disorder characterized by lenticular and pupillary ectopia. Recent speculation on its pathogenesis is based on clinical observation and includes a neuroectodermal defect or persistence of fetal vasculature. None of these reports included histopathology or imaging studies. STUDY(More)
PURPOSE To determine whether elevated plasma homocysteine and serum high sensitivity C-reactive protein (hsCRP) levels, two established risk factors of vascular diseases, are associated with polypoidal choroidal vasculopathy (PCV). DESIGN Retrospective case-control study. METHODS One hundred and nineteen consecutive patients with PCV and 119 matched(More)
PURPOSE To investigate whether daily changes in ambient air pollution were associated with an increased risk of central retinal artery occlusion (CRAO). DESIGN Retrospective population-based cohort study. PARTICIPANTS We identified patients newly diagnosed with CRAO between 2001 and 2013 in a representative database of 1 000 000 patients that were(More)
Amiodarone, an antiarrhythmic agent, has been associated with visual loss secondary to optic neuropathy. The reported mean duration of amiodarone use before visual loss is about 9 months. Patients receiving amiodarone have a 2-fold increased risk of developing optic neuropathy, especially in males and possibly in patients with longer duration of treatment.(More)
PURPOSE To investigate whether amiodarone use is associated with an increased risk of optic neuropathy. DESIGN Retrospective population-based cohort study. PARTICIPANTS Patients newly treated with amiodarone between 2005 and 2009 were identified from the Taiwan National Health Insurance Research Database. For each case patient, the study also included 4(More)